Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Bernard Escudier(Institut Gustave Roussy), Stéphane Oudard(Hôpital Européen Georges-Pompidou), Thomas E. Hutson(Texas Oncology), Camillo Porta(University of Pavia), Sergio Bracarda(Azienda Ospedaliera di Perugia), Viktor Grünwald(Medizinische Hochschule Hannover), John A. Thompson(Seattle Cancer Care Alliance), Robert A. Figlin(City Of Hope National Medical Center), Norbert Hollaender(Novartis (United States)), Gladys Urbanowitz(Novartis (United States)), William J. Berg(Novartis (United States)), Andrea Kay(Novartis (United States)), David Lebwohl(Novartis (United States)), Alain Ravaud(Hôpital Saint-André)
Cited by 3,010
Abstract
Related Papers
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k